About Managing Director

Jeannie Kim, BSc, MEM, MBA

Brings over 20 years of Life Science global corporate development and strategy leadership in enterprise transformations (ie. growth initiatives/turn-arounds) and building critical mass for pioneering and emerging technologies through strategy, portfolio prioritization, and partnership ecosystems, as a consultant, advisor, and fractional executive (CBO/CBDO/COO/CSO/CMO).

With a comprehensive background across traditional pharmaceuticals/biotech, med tech/techbio, and medical devices, she specializes in innovations that leverage their synergies and intersections to advance personalized medicine and/or improve access.

[eg. companion diagnostics (sequencing to POC in global health), molecular imaging/radioligands, robotic radioguided surgery/imaging (radiopharmaceutical-based surgical guidance), digital health applications for decentralized trials (interoperability), AI applications in discovery/translational research.]

Originally trained as an engineer, she began her career designing surgical instruments & dialysis devices for Baxter International and values creativity in both engagement and data-driven strategies over cookie-cutter approaches for novel scientific/technological innovations.

Her corporate development background began on the buy-side with multinationals (Pharmacia/Pfizer, Philips Medical). Her first out-license/sell-side deal assignment to secure a collaboration investment partner for a drug-device program with zero external interest for over 2 years was initially earmarked for liquidation. In a little over a year, the innovative program ultimately became a multinational partnership with Bayer with a subsequent platform acquisition by Novartis , collectively valued up to $300 million for Nektar. She’s since had an emphasis on working with small pioneering teams across multinationals, non-profits, and start-ups, seeking to move the needle in healthcare.

Ms. Kim has successfully closed over 50 transactions, >$5B in aggregate across (in/out) licensing, equity, and M&A -- in rare/orphan diseases, neurology/ophthalmology, metabolic disorders, oncology, immunology, women’s health, and infectious disease.

She’s held global corporate business development & strategy leadership roles and engagements with multinationals from Pfizer/Pharmacia/GD Searle (US, UK, MENEA), Johnson& Johnson, Philips Medical Systems, Pulmonary Unit of Nektar (now Novartis), Thermo Fisher Scientific – Clinical Sequencing, Biogen, GSK plc, including global health public-private partnerships with PATH/GSK/Gates Foundation and Medicines360. She believes in compassionate leadership and enjoys leveraging her experience to drive growth for inspiring innovations, organizations, and people.

Ms.Kim holds a BSc in Biomedical/Mechanical Engineering, joint degree in Masters in Engineering Management and Masters in Business Administration from Northwestern University and Northwestern’s Kellogg School of Management, respectively. JD studies in Business Law/Animal (Environmental) Law at Lewis & Clark Northwestern School of Law. Stanford Medicine certification in Evaluations of AI applications in Healthcare.

Member of Northwestern’s Alumni Admissions Council. Kellogg Womens Forum, with strong interest in the arts, animal welfare, wildlife conservation, and poverty alleviation.